XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues $ 43,371 $ 35,694 $ 142,678 $ 120,604
Cost of products sold 33,752 27,012 108,713 88,889
Gross profit 9,619 8,682 33,965 31,715
Operating expenses:        
Research and development 2,855 2,101 7,577 5,854
Selling, general and administrative 7,715 6,070 21,684 17,370
Total operating expenses 10,570 8,171 29,261 23,224
Operating income (951) 511 4,704 8,491
Other (expense) income:        
Interest and financing expense 992 173 3,016 1,111
Miscellaneous expense (income) (192) (15) (120) (426)
Total other expense 800 158 2,896 685
Income before income taxes (1,751) 353 1,808 7,806
Income tax provision (504) 74 306 1,630
Net income (1,247) 279 1,502 6,176
Net income (loss) attributable to non-controlling interest (27) 21 (22) 58
Net income attributable to Ultralife Corporation (1,220) 258 1,524 6,118
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]        
Foreign currency translation adjustments (238) 811 948 576
Comprehensive income attributable to Ultralife Corporation $ (1,458) $ 1,069 $ 2,472 $ 6,694
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ (0.07) $ 0.02 $ 0.09 $ 0.37
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ (0.07) $ 0.02 $ 0.09 $ 0.37
Weighted average shares outstanding – basic (in shares) 16,646 16,625 16,638 16,530
Potential common shares (in shares) 0 249 61 212
Weighted average shares outstanding - diluted (in shares) 16,646 16,874 16,699 16,742